The Medical Letter on Drugs and Therapeutics
Darbepoetin (Aranesp) - A long-acting Erythropoietin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Darbepoetin (Aranesp) - A long-acting Erythropoietin
Darbepoetin alfa (Aranesp) has been approved by the FDA for treatment of anemia caused by chronic renal disease and will probably also be approved for use in patients with cancer..
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Darbepoetin (Aranesp) - A long-acting Erythropoietin
Article code: 1120a
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.